The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Premier Diagnostic Health Service Inc.

Monday Deal Review: February 24, 2014

  Welcome to your Monday Biotech Deal Review for February 24, 2014!

Read more of this post

Monday Deal Review: February 10, 2014

  Welcome to your Monday Biotech Deal Review for February 10, 2014! The big news this week was Valeant’s proposed acquisition of another skin care innovator, PreCision Dermatology, for $475 million. Hit the break for more details on this as well as the rest of the week’s major biotech news.

Read more of this post

Monday Deal Review: October 14, 2013

  Welcome to your Monday Biotech Deal Review for October 14, 2013!

Of particular note this week is the innovative collaboration between Sirona Biochem and Bloom Burton & Co. The venture seeks to develop and commercialize new therapeutics in the areas of inflammation and infectious disease. Such an arrangement purports to take advantage of Sirona’s proprietary fluorination technology platform, and Bloom Burton’s knowledge of the market and expertise in commercialization, delivering to market products targeted towards rare or neglected inflammatory diseases and bacterial resistance. This model shows significant promise, so look to this space to see how the relationship progresses.

Hit the break to get the full scoop on the week’s major stories!

Read more of this post

Monday Deal Review: October 7, 2013

  Welcome to your Monday Biotech Deal Review for October 7, 2013! A busy week saw significant activity in both the financing and commercial agreement spaces.  Of note is MedMira recieving a $6.1 million equity investment.

Hit the break for the full rundown of the week’s major biotech news! And thanks again to Jennifer Ng of Norton Rose Fulbright for helping out with this week’s post.

Read more of this post

Monday Deal Review: February 4, 2013

Welcome to your Monday Biotech Deal Review for February 4, 2013! This week saw significant activity in the sector generally  On the M&A side, Valeant continued their ongoing acquisition strategy, buying the Russian Natur Product International, a primarily OTC private pharma company. Gilead’s acquisition of YM Biosciences took one step closer to completion as YM shareholders approved the statorily mandated vote to approve the plan of arrangement that will facilitate the arrangement. Court approval is now required as one of the final steps. Microbix was also involved in the week’s M&A activity, having sold its water for injections business to Irvine Scientific. The there was also significant investment activity this week, including Biosenta announcing a new private placement.

See detail on these and the the rest of the week’s major biotech stories by clicking through!

Read more of this post

Monday Biotech Deal Review: September 12, 2011

Welcome to your Monday Biotech Deal Review for September 12, 2011.  We hope everyone had a restful labo(u)r day long weekend, both north and south of the border.  This week’s biotech deal review is a double feature owing to last week’s holiday.  There has been a lot of activity in the past two weeks, including the announcement of a friendly takeover bid of Afexa by Valeant (Afexa is already the target of a hostile bid by Paladin).  Read on to learn more.  Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 129 other followers